Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.

From the monthly archives: September, 2018

We are pleased to present below all posts archived in 'September, 2018'. If you still can't find what you are looking for, try using the search box.

Inivata Strengthens Senior Leadership Ahead of Next Stage of Company Growth

Inivata, a leader in liquid biopsy, today, 12 September, announces the strengthening of its senior leadership team with the appointment of Clive Morris, formerly Chief Medical Officer, as Chief Executive Officer, Stacy Chick as Chief Commercial Officer and Thomas Schlumpberger as VP Business Development.

Read the rest of entry »

Inivata to Present New Clinical Data on the Utility of the InVision® Liquid Biopsy Platform in Advanced Non-Small Cell Lung Cancer at the World Conference on Lung Cancer

Inivata, a leader in liquid biopsy announces that the company and its world-leading collaborators will showcase cutting-edge data in two mini oral presentations and six posters at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC) 23 - 26 September in Toronto. The details are as follows:

Read the rest of entry »

BioCity Group appoints leading life sciences expert to the Board to drive growth

BioCity, the Nottingham-headquartered life sciences incubation business, has appointed Stuart Henderson to the Board to help drive its growth and further strengthen its connections within the life sciences sector.

Read the rest of entry »

BTG snaps up Ireland’s Novate Medical in a deal worth up to $150M

BTG, a British specialist healthcare group has acquired Novate Medical, a pulmonary embolism-focused medtech startup. While the upfront fee is a modest $20 million, BTG is on the hook for up to $130 million more in potential commercial and sales-related milestone payments. 

Under the deal, BTG will pick up Novate’s Sentry device, a bioconvertible filter for the inferior vena cava (IVC) that scored FDA clearance last year. It is indicated for the prevention of recurrent pulmonary embolism (PE), or the blockage of a major artery in the lung usually caused by a blood clot that has traveled from elsewhere in the body. The Sentry filter is indicated for patients at high risk of PE for whom anticoagulants have failed or are contraindicated, and in patients requiring emergency treatment for PE. 

BTG plans to launch the device in the U.S. in the second half of its 2018/2019 fiscal year. 

For more information please read the article.

Key Enabling Technologies (KETs) Observatory initiative of the European Commission.

The KETs Observatory is an online monitoring platform that aims to provide the EU, national and regional policy makers and business stakeholders with quantitative and qualitative information on the deployment of Key Enabling Technologies (KETs) both within the EU and in comparison with other world regions (e.g. East Asia, North America). As contract holders of the second phase of this initiative, PricewaterhouseCoopers (PwC) are currently working on on patents, production, employment and trade for each key enabling technology. The data are available in a database format, as well as in the individual country prupdating and advancing the KETs Observatory website. PwC are publishing the most recent sets of quantitative data ofiles for EU and non-EU countries. Additionally, they have published a series of analytical reports on specific promising KETs-based products, that have a high potential for large-scale manufacturing in Europe. No comparable initiative exists on this scale. This type of informatio ...

Read the rest of entry »

Evox raises €37m in Series B Round

Oxford, UK: Exosome drug delivery specialist Evox Therapeutics Ltd has closed a €37.1m (£35.5m) Series B financing round led by Redmile Group and significant contributions from GV (Google Ventures) and Cowen Healthcare Investments.

Read the rest of entry »

Ossianix and Novo Nordisk sign Research and Option Agreement on Blood Brain Barrier delivery technology for proteins in diabetes and other metabolic diseases

Philadelphia, PA, USA: Ossianix, Inc. today announced a research collaboration and option agreement with Novo Nordisk to deliver therapeutic molecules in diabetes and other metabolic diseases across the Blood Brain Barrier (BBB) to the brain.

Read the rest of entry »

Pages: Previous12NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.